


Supplementary informations

Supplementary Figures



ABO: MW 180

Fig. S1 Chemical structures of ABO, 6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine.




Fig.S2 Western blot analysis and quantification of ANXA7 protein level. Overexpression (pCVM-ANXA7) and knockdown (siANXA7) of ANXA7 were performed. Protein levels were normalized to that of β -actin. Data are mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, # $p < 0.05$, ## $p < 0.01$, $n = 3$.




Fig.S3 Double immunohistochemical staining showed that ANXA7 (red) and PC-PLC (green) exhibited agglomeration and colocalization after different treatment in HUVECs. Overexpression (pCMV-ANXA7) and knockdown (siANXA7) of ANXA7 were performed. Overlays of the red and green signal with a yellow colour indicated co-localization. Bar represents 16 μ m.




Fig.S4 Dual immunofluorescence for CD31 and LC3 of en face aortic arch. (A) Confocal images of en face aortic arch labeled with DAPI (blue), rat-anti-CD31 (red) and rabbit-anti-LC3 (green). (B) The bar chart separately showed quantification of

LC3 dots per cell in the endothelium. Data are mean \pm SEM. * $p < 0.05$ vs. baseline, # $p < 0.05$, ## $p < 0.01$ vs. control, $n = 6$.




Fig.S5 Experimental design of 4 experimental protocols. ABO low-dosage: ABO-LD; ABO high-dosage: ABO-HD.




Fig.S6 The normal rabbit IgG control demonstrated the specificity of the antibody against p62, LC3, ANXA7 and PC-PLC. Bar = 60 μ m.

Table S1. Measurement of organ coefficients of mice after treatment with ABO.

Groups	Heart (%)	Liver (%)	Spleen (%)	Lung (%)	Kidney (%)	Brain (%)
Control	0.41 \pm 0.03	4.85 \pm 0.41	0.50 \pm 0.03	0.59 \pm 0.01	1.21 \pm 0.12	0.83 \pm 0.04
ABO-LD	0.40 \pm 0.01	4.90 \pm 0.40	0.53 \pm 0.04	0.57 \pm 0.02	1.14 \pm 0.11	0.86 \pm 0.05
ABO-HD	0.41 \pm 0.05	4.84 \pm 0.38	0.51 \pm 0.02	0.61 \pm 0.08	1.21 \pm 0.14	0.84 \pm 0.09